Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Durie

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Future Oncology (London, England)|April 12, 2017
End points and statistical considerations in immuno-oncology trials: impact on multiple myelomaAntje Hoering, Brian Durie, Hongwei Wang, et al.
Expert Review of Hematology|January 17, 2014
The utility of newer imaging techniques as predictors of clinical outcomes in multiple myelomaAnnamaria Brioli, Gareth J Morgan, Brian Durie, et al.
The Oncologist|April 27, 2020
Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient EmpowermentHeinz Ludwig, Susie Novis Durie, Angela Meckl, et al.
Journal of Medical Economics|January 4, 2013
Total cost comparison in relapsed/refractory multiple myelomaBrian Durie, Gary Binder, Chris Pashos, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 25, 2022
Patient and Caregiver Experience Decision Factors in Treatment Decision Making: Results of a Systematic Literature Review of Multiple Myeloma Decision AidsMimi Choon-Quinones, Dirk Hose, Zoltán Kaló, et al.
Leukemia & Lymphoma|October 1, 2015
Risk of multiple myeloma in a case-spouse studyGabriella Andreotti, Michael Katz, Antje Hoering, et al.
Journal of Medical Economics|November 18, 2022
Beyond medicines' barriers: exploring the true cost of multiple myelomaMimi Choon-Quinones, Tamás Zelei, Mike Barnett, et al.
Journal of Medical Economics|November 8, 2022
Systematic literature review of health economic models developed for multiple myeloma to support future analysesMimi Choon-Quinones, Tamás Zelei, Bertalan Németh, et al.
Cells|January 8, 2023
Investigation of Rare Non-Coding Variants in Familial Multiple MyelomaYasmeen Niazi, Nagarajan Paramasivam, Joanna Blocka, et al.
The Lancet. Oncology|February 13, 2018
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 studyNoopur Raje, Evangelos Terpos, Wolfgang Willenbacher, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Future Oncology (London, England)|April 12, 2017
End points and statistical considerations in immuno-oncology trials: impact on multiple myelomaAntje Hoering, Brian Durie, Hongwei Wang, et al.
Expert Review of Hematology|January 17, 2014
The utility of newer imaging techniques as predictors of clinical outcomes in multiple myelomaAnnamaria Brioli, Gareth J Morgan, Brian Durie, et al.
The Oncologist|April 27, 2020
Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient EmpowermentHeinz Ludwig, Susie Novis Durie, Angela Meckl, et al.
Journal of Medical Economics|January 4, 2013
Total cost comparison in relapsed/refractory multiple myelomaBrian Durie, Gary Binder, Chris Pashos, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 25, 2022
Patient and Caregiver Experience Decision Factors in Treatment Decision Making: Results of a Systematic Literature Review of Multiple Myeloma Decision AidsMimi Choon-Quinones, Dirk Hose, Zoltán Kaló, et al.
Leukemia & Lymphoma|October 1, 2015
Risk of multiple myeloma in a case-spouse studyGabriella Andreotti, Michael Katz, Antje Hoering, et al.
Journal of Medical Economics|November 18, 2022
Beyond medicines' barriers: exploring the true cost of multiple myelomaMimi Choon-Quinones, Tamás Zelei, Mike Barnett, et al.
Journal of Medical Economics|November 8, 2022
Systematic literature review of health economic models developed for multiple myeloma to support future analysesMimi Choon-Quinones, Tamás Zelei, Bertalan Németh, et al.
Cells|January 8, 2023
Investigation of Rare Non-Coding Variants in Familial Multiple MyelomaYasmeen Niazi, Nagarajan Paramasivam, Joanna Blocka, et al.
The Lancet. Oncology|February 13, 2018
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 studyNoopur Raje, Evangelos Terpos, Wolfgang Willenbacher, et al.
Pageof 4